Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference
06 November 2020 - 8:01AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on
accelerating the development of medicines to treat cancer and other
serious diseases, today announced that Mike Sherman, Chief
Executive Officer, will present a corporate overview and program
update at the Credit Suisse 29th Annual Healthcare Conference on
Thursday, November 12, 2020 at 4:15 p.m. ET.
A live audio webcast of the presentation will be available on
the Investor Relations section of Chimerix's website
at ir.chimerix.com, where it will be archived for
approximately 90 days.
About Chimerix
Chimerix is a development-stage biopharmaceutical company
dedicated to accelerating the advancement of innovative medicines
that make a meaningful impact in the lives of patients living with
cancer and other serious diseases. Its two clinical-stage
development programs are dociparstat sodium (DSTAT) and
brincidofovir (BCV).
DSTAT is a potential first-in-class glycosaminoglycan compound
derived from porcine heparin that, compared to commercially
available forms of heparin, may be dosed at higher levels without
associated bleeding-related complications. DSTAT is being studied
in a Phase 2/3 trial to assess safety and efficacy in adults with
acute lung injury with underlying COVID-19. A Phase 3 trial
protocol to study DSTAT in acute myeloid leukemia has been
developed in alignment with the US Food and Drug Administration
(FDA) and site activation is expected in early 2021. BCV is an
antiviral drug candidate in development as a medical countermeasure
for smallpox and is currently under review for regulatory approval
in the United States. For further information, please visit the
Chimerix website, www.chimerix.com.
CONTACT:
Investor
Relations: Michelle
LaSpaluto919 972-7115ir@chimerix.com
Will O’ConnorStern Investor
Relations212-362-1200will@sternir.com
Media:David SchullRusso
Partners858-717-2310David.Schull@russopartnersllc.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Apr 2024 to May 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From May 2023 to May 2024